Dysmenorrhea affects up to 90% of menstruating women, with moderate to severe pain impacting 1 in 3 women’s daily function, productivity, and mental health.
Global Market Overview:
-Dysmenorrhea therapeutics market: USD 10.9 billion (2024)
-Primary treatments today include NSAIDs and hormonal contraceptives
-Consumers increasingly seeking natural, non-hormonal, and non-opioid solutions
Unmet Needs:
-Natural, non-invasive options
-Better symptom management without hormonal impact
-Convenient, patient-friendly delivery (e.g. gummies)
Eve’s first pharmaceutical product, Dyspro, is a clinically-informed gummy designed to address these gaps - currently in stability testing ahead of TGA submission.
.jpg)
By combining Nextract’s proprietary solubility IP with consumer-preferred formats like gummies and softgels, Eve is unlocking access to markets traditionally dominated by outdated delivery mechanisms.We are currently progressing:
-TGA approval for Dyspro (Dysmenorrhea)
-Preclinical development of Tadalafil softgel (ED)
-Licensing discussions for delivery IP
-Strategic partnerships across MENA, Australia, and the US
Dyspro is a prescription only product. Speak to your GP or a prescriber for more information.
